Site 'Main' Navigation:

There are no approved drugs that prevent progression to liver cirrhosis.

We're working to change that.

Events and
Presentations

May 2, 2018 4:30 PM EDT : Conatus Pharmaceuticals First Quarter 2018 Financial Results
Open Webcast
May 02

View All

Latest News
from Conatus

Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
July 02

More News

Our
Programs

Emricasan is a first-in-class, orally active caspase inhibitor designed to reduce the activity of ...

Learn More

Liver cirrhosis kills 32,000 Americans each year.

The only "cure" is a transplant.

Learn More

By 2020, the leading cause of liver transplants is expected to be NASH.

We're moving toward
registration with an
initial focus on
NASH cirrhosis.

Registration Plans